Norges Bank Makes New $103.30 Million Investment in Henry Schein, Inc. (NASDAQ:HSIC)

Norges Bank bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the 4th quarter, Holdings Channel.com reports. The fund bought 1,492,793 shares of the company’s stock, valued at approximately $103,301,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HSIC. Smartleaf Asset Management LLC increased its stake in Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock worth $52,000 after acquiring an additional 143 shares during the period. CIBC Asset Management Inc increased its stake in Henry Schein by 1.0% in the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock valued at $1,235,000 after acquiring an additional 169 shares during the last quarter. Metis Global Partners LLC raised its position in Henry Schein by 4.7% during the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock valued at $291,000 after purchasing an additional 187 shares in the last quarter. Central Pacific Bank Trust Division lifted its stake in Henry Schein by 2.0% during the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company’s stock worth $706,000 after purchasing an additional 200 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its holdings in shares of Henry Schein by 5.0% in the 4th quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company’s stock valued at $294,000 after purchasing an additional 203 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In related news, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares of the company’s stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Philip A. Laskawy sold 2,604 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total value of $184,988.16. Following the sale, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC opened at $69.07 on Wednesday. The stock has a 50-day moving average of $74.42 and a 200-day moving average of $72.67. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The company has a market cap of $8.58 billion, a PE ratio of 28.42, a P/E/G ratio of 2.13 and a beta of 0.90.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period in the previous year, the company earned $0.66 earnings per share. Henry Schein’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on HSIC shares. Barrington Research restated an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a research report on Wednesday, February 26th. Mizuho assumed coverage on shares of Henry Schein in a report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 price target on the stock. Wells Fargo & Company started coverage on shares of Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price objective for the company. Jefferies Financial Group raised their price objective on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Finally, UBS Group lowered their target price on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.10.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.